| Title |
Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents
|
|---|---|
| Published in |
Breast Cancer Research and Treatment, October 2010
|
| DOI | 10.1007/s10549-010-1224-1 |
| Pubmed ID | |
| Authors |
Pamela J. Goodwin, Vuk Stambolic, Julie Lemieux, Bingshu E. Chen, Wendy R. Parulekar, Karen A. Gelmon, Dawn L. Hershman, Timothy J. Hobday, Jennifer A. Ligibel, Ingrid A. Mayer, Kathleen I. Pritchard, Timothy J. Whelan, Priya Rastogi, Lois E. Shepherd |
| Abstract |
Metformin, an inexpensive oral agent commonly used to treat type 2 diabetes, has been garnering increasing attention as a potential anti-cancer agent. Preclinical, epidemiologic, and clinical evidences suggest that metformin may reduce overall cancer risk and mortality, with specific effects in breast cancer. The extensive clinical experience with metformin, coupled with its known (and modest) toxicity, has allowed the traditional process of drug evaluation to be shortened. We review the rationale for a modified approach to evaluation and outline the key steps that will optimize development of this agent in breast cancer, including discussion of a Phase III adjuvant trial (NCIC MA.32) that has recently been initiated. |
Mendeley readers
The data shown below were compiled from readership statistics for 83 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Italy | 2 | 2% |
| Netherlands | 1 | 1% |
| Brazil | 1 | 1% |
| United Kingdom | 1 | 1% |
| Japan | 1 | 1% |
| United States | 1 | 1% |
| Unknown | 76 | 92% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 14 | 17% |
| Student > Bachelor | 10 | 12% |
| Professor > Associate Professor | 10 | 12% |
| Student > Ph. D. Student | 9 | 11% |
| Student > Postgraduate | 8 | 10% |
| Other | 20 | 24% |
| Unknown | 12 | 14% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 31 | 37% |
| Agricultural and Biological Sciences | 18 | 22% |
| Biochemistry, Genetics and Molecular Biology | 4 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 5% |
| Immunology and Microbiology | 2 | 2% |
| Other | 8 | 10% |
| Unknown | 16 | 19% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 August 2021.
All research outputs
#4,749,004
of 22,992,311 outputs
Outputs from Breast Cancer Research and Treatment
#898
of 4,677 outputs
Outputs of similar age
#21,064
of 99,999 outputs
Outputs of similar age from Breast Cancer Research and Treatment
#12
of 42 outputs
Altmetric has tracked 22,992,311 research outputs across all sources so far. Compared to these this one has done well and is in the 76th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,677 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one has gotten more attention than average, scoring higher than 74% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 99,999 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.
We're also able to compare this research output to 42 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 64% of its contemporaries.